Facial fat grafting

How much of the grafted fat actually survives — and why it matters

The single most important biological fact about facial fat grafting is that not all of the fat injected becomes permanent tissue. Clinical experience and the published literature generally put long-term survival somewhere in the region of 40 to 70 percent of the volume injected, with the remainder resorbed by the body over the first three to six months as cells that never regained a blood supply are cleared away. Where any individual patient falls within that range depends on several factors at least partly within the surgeon’s control: how the fat is harvested, how it is processed, and, most of all, how finely and evenly it is placed during injection.

Survival is also zone-dependent. Areas with a thick, well-vascularised, relatively immobile recipient bed — the mid-cheek, the temple, the pre-jowl area — tend to retain fat more reliably than thin-skinned, highly mobile areas such as the lips or the tissue around the eyes. This is one reason a surgeon may be confident grafting the cheeks generously in one session while being deliberately conservative, or recommending filler instead, for the tear trough or lips.

The same underlying biology applies to fat transferred to the breast or buttocks, but survival rates reported in the face are generally at the higher end of the range quoted for other donor sites, usually attributed to the face’s unusually rich blood supply and to the smaller, more carefully distributed volumes used per pass.

In practice, this biology shapes how the procedure is planned and how success is judged. Surgeons routinely overfill each area at surgery, anticipating that a predictable proportion will not survive. It also means the result cannot be properly assessed until swelling has resolved and resorption has run its course, typically by three to six months, not at the two-week mark when the face still looks its most dramatic. A first graft under-surviving in a particular area is not unusual, and a second, smaller top-up session three months or more later is a normal part of achieving the final planned volume, not a sign that anything went wrong.

The rare but serious risk: vascular occlusion from facial fat injection

The complication that shapes how facial fat grafting is taught, more than any other, is the possibility that injected fat enters an artery instead of the soft tissue around it. The face has a dense, interconnected network of small arteries close to the skin surface in several specific zones — most notably the glabella, the nose, the temple and the nasolabial fold — and these vessels connect, directly or through anastomoses, to the ophthalmic artery that supplies the retina and, further back, to branches of the internal carotid system that supply the brain. If fat is injected under enough pressure into one of these arteries, it can travel backward against normal blood flow and then forward again into the ophthalmic or central retinal artery, blocking flow at the other end. Documented consequences in the case-report literature include sudden, usually permanent vision loss in one eye, and, less often, stroke.

It is important to be precise about how rare this is: the great majority of facial fat grafting procedures are performed without this complication occurring. It appears to be less frequent with fat than with some dermal fillers, partly because fat grafting uses blunt-tipped cannulas rather than sharp needles, which are less likely to pierce an artery wall outright. But a blunt cannula does not make the risk zero, which is why it is categorised as very rare rather than absent, and treated as the most serious possible complication of this procedure.

The practical response to this risk, in a well-run practice, is almost entirely about technique and anatomical knowledge. Surgeons who graft the face regularly are trained to know the three-dimensional course of the supratrochlear, supraorbital, dorsal nasal, angular and superficial temporal arteries in each danger zone, and to work in the safer tissue planes where those vessels are better understood and less exposed. Injection is done slowly, at low pressure, in small aliquots well under a tenth of a millilitre per pass, with the cannula kept constantly moving rather than held still to deposit a bolus. None of this is something a patient can verify by eye, which is why asking directly about a surgeon’s training, case volume and familiarity with this specific complication is a reasonable and informed question to raise at consultation.

Fat grafting versus dermal filler: longevity, reversibility and natural feel

Fat and hyaluronic acid filler are often presented as interchangeable ways to restore facial volume, but they behave quite differently once in the tissue, and the differences matter more than the headline comparison of cost or convenience. Filler is immediate and fully adjustable at the time of treatment: an injector can add more, stop early, or dissolve what has already been placed within minutes using hyaluronidase. Fat has no equivalent rescue option. Once it has revascularised and become living tissue, it cannot be dissolved away; a poor result, a lump, or an overcorrected area can usually only be addressed with time, massage, or, in persistent cases, surgical removal of the affected pocket.

Longevity runs the opposite direction. Most hyaluronic acid fillers last somewhere between six and eighteen months before the body gradually breaks them down, meaning maintenance treatment is needed indefinitely to sustain the result. The fraction of a fat graft that survives the initial three to six months is generally considered permanent tissue, behaving like any other fat in the body from that point on — it does not need to be topped up on a schedule, although a very thin patient or one with substantial future weight loss will see it shrink along with their other fat stores.

There is also a difference in what the two approaches do to the surrounding tissue. Fat, because it is composed of living adipocytes, stromal cells and usually some stem-cell-containing fraction, has been reported in some studies to improve the quality of overlying skin beyond pure volume replacement, although this regenerative effect is less precisely quantified than the volumizing effect and claims about it should be read cautiously. Filler adds volume without this additional tissue effect.

In practice, the choice is rarely purely one or the other. Many surgeons use filler for fine-tuning, for mobile or delicate areas such as the lips and tear trough, and reserve fat grafting for broader structural volume restoration in the cheeks, temples and jawline, or for patients already having liposuction elsewhere who would rather use that fat than discard it.

Combining fat grafting with a facelift or eyelid surgery

A facelift and a fat graft solve different problems, which is why the two are so often performed together rather than as alternatives. A facelift addresses descent: skin, fat and the underlying SMAS layer that has stretched and dropped under gravity, corrected by repositioning and securing that tissue along a lifted vector. What it does not do is replace volume the face has lost outright through fat compartment shrinkage and bone remodelling, because there is nothing to lift back into a hollow temple or flattened cheek if the volume that used to be there is simply gone. Fat grafting fills that gap, and the two together generally produce a more natural, rested look than either alone. A facelift performed on a face with significant volume loss but no added volume can look tight or “pulled” rather than rejuvenated.

In practice, many surgeons who offer facelifts routinely add fat to the cheeks, temples, and sometimes the pre-jowl sulcus and lips, in the same operation, harvesting it from the abdomen or thighs while the patient is already under anaesthesia for the lift.

Eyelid surgery raises a related but distinct consideration. Blepharoplasty typically removes or repositions excess skin and sometimes fat pockets around the eyes, but it does not fill the hollow that often forms at the junction between the lower eyelid and the upper cheek as this area loses volume with age — removing too much fat during blepharoplasty without a plan for that volume relationship can leave the junction looking more hollow than before. Fat grafting to the tear trough and upper cheek, performed either at the same time as blepharoplasty or afterward once healing is complete, can smooth this transition. Because both procedures affect the same small, delicate area from different directions, surgeons who combine them need to plan the volumes carefully together, to avoid either an over-corrected, puffy result or an under-corrected hollow.

Why larger volume restoration may need more than one session

For a patient with a moderate, localised volume deficit, a single well-executed fat grafting session is often enough to achieve the planned result once overcorrection resolves and the surviving fat stabilises. But for larger or more complex volume loss, staging treatment across two or more sessions is standard, considered practice rather than a sign the first attempt fell short.

There are two reasons for this. The first is biological: fat survival in any given area cannot be predicted with precision in advance, so the only reliable way to know how much a particular zone needs topped up is to see how much of the first graft actually survived, which is not clear until three to six months after surgery. Operating again before that point risks adding fat on top of tissue still swollen or still resorbing. The second reason is about what any single session can safely achieve: placing a very large volume of fat into one area at once increases the risk of central-necrosis and lumpiness problems, because there is a practical limit to how much new fat a given recipient bed can revascularise at once.

A staged approach therefore spreads both the volume and the risk across sessions set several months apart, typically starting with a deliberately conservative first graft, assessing the result once fully settled, and then adding a second, usually smaller, top-up to the areas that need it.

For patients travelling abroad for surgery, this has a practical scheduling implication worth raising at consultation: a realistic plan for large volume restoration may involve two trips several months apart rather than one, and it is worth clarifying in advance, and in the price quoted, whether a second session is costed as a planned part of treatment or as a separate booking only if needed.

Who is not a good candidate for facial fat grafting

Facial fat grafting depends on two things not true for every interested patient: having enough donor fat to harvest, and being able to tolerate a result that develops gradually and cannot be precisely predicted in advance. Patients who are very lean, with little subcutaneous fat on the abdomen, flanks or thighs, often simply do not have enough donor tissue to harvest a useful volume, and attempting to take fat from an already thin area carries its own risk of visible donor-site contour irregularity. For these patients, dermal filler, which requires no donor site at all, is usually the more realistic option.

Patients who want a large, precisely controlled, immediately visible change in a single sitting are also generally not well served by fat grafting, even with adequate donor fat. The procedure’s biology makes it a poor fit for anyone needing certainty about the exact outcome before committing. The same applies to patients who want the option to adjust or reverse the result if unsatisfied; because fat cannot be dissolved away the way filler can, a patient who values reversibility highly is better matched to filler, at least for an initial trial of a new look.

Medical factors that impair small-vessel healing reduce fat survival specifically. Uncontrolled diabetes can impair the microvascular ingrowth that grafted fat depends on to survive, independent of its other surgical risks. Smoking has the same effect through nicotine-induced vasoconstriction, affecting both donor-site healing and the graft’s ability to revascularise in its new location. Active skin infection at a planned injection site is a straightforward contraindication until resolved.

Finally, it is worth being direct about the vascular risk discussed above: the technique is safe in experienced, well-trained hands, but it is not a procedure where corner-cutting on technique in high-risk zones such as the glabella and temple has a wide margin for error.